Details:
The newly added patent cover Confo’s well-established small molecule screening capabilities, which led to the discovery of CFTX-1554 designed to address peripheral neuropathic pain while avoiding centrally mediated side effects, such as addiction and sedation.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
The ReS3-T program is the result of a collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3). ReS3-T acts via a novel proprietary target, Pde6δ, to control neuronal activity.
Lead Product(s): ReS3-T
Therapeutic Area: Neurology Product Name: ReS3-T
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Neurological Disorders
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 04, 2021
Details:
Acquisition of Handl Therapeutics BV augments UCB’s existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid technology platform and capabilities.
Lead Product(s): AAV-mediated gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: UCB Pharma S.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 12, 2020
Details:
Confo has applied its proprietary, fragment-based drug discovery and structure-guided drug design technologies to identify CFTX-1554, a novel inhibitor of angiotensin II type 2 receptor, or AT2R, a clinically validated target for the treatment of neuropathic pain.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020